中国P站

Ovarian Cancer; Radiotherapy; Precision Radiotherapy; Adaptive Radiotherapy; Image-Guided Radiotherapy; Intensity-Modulated Radiation Therapy; Combination Therapy; Proton Therapy; Brachytherapy; Stereotactic Body Radiation Therapy

Introduction

Recent advancements in radiotherapy for ovarian cancer are significantly improving treatment outcomes and patient quality of life, marked by the integration of advanced imaging techniques like MRI and PET-CT for precise tumor delineation, leading to more accurate dose delivery and reduced toxicity to surrounding healthy tissues [1].

Precision radiotherapy, encompassing image-guided brachytherapy and intensity-modulated radiation therapy (IMRT), is crucial for managing locally advanced ovarian cancer, enabling higher doses to the tumor while sparing organs at risk and minimizing side effects [2].

The exploration of novel radioisotopes and combination therapies, particularly with immunotherapy and targeted agents, also shows great promise in overcoming treatment resistance and improving survival rates in ovarian cancer treatment [1].

The integration of radiotherapy with systemic treatments, such as chemotherapy and targeted therapies, is a key area of ongoing research, investigating optimal sequencing and concurrent delivery to achieve synergistic anti-tumor effects [3].

Radiotherapy techniques are evolving to improve dose escalation in the pelvic and para-aortic regions, common sites for recurrence in ovarian cancer, with techniques like volumetric modulated arc therapy (VMAT) offering superior dose conformity compared to traditional IMRT [4].

The role of definitive radiotherapy in specific subsets of ovarian cancer, such as in elderly patients or those with unresectable disease, is being re-evaluated with these advanced modalities, highlighting its continued importance [2].

Quality assurance and adaptive planning are critical for maximizing the benefits of modern radiotherapy in ovarian cancer, involving meticulous contouring of organs at risk and robust dose calculation algorithms [6].

Adaptive strategies, informed by daily imaging, help to account for inter- and intra-fraction variations in tumor size and position, ensuring the planned dose is delivered accurately to the target volume [6].

The use of proton therapy in gynecologic malignancies, including ovarian cancer, is being explored for its potential to reduce dose to organs at risk, especially in pelvic irradiation settings [7].

The identification of biomarkers that predict response to radiotherapy in ovarian cancer is a critical unmet need, with research focused on genomic, proteomic, and imaging biomarkers to personalize treatment and improve efficacy [8].

Description

Recent advancements in radiotherapy for ovarian cancer are significantly improving treatment outcomes and patient quality of life, characterized by the integration of advanced imaging techniques like MRI and PET-CT for precise tumor delineation, leading to more accurate dose delivery and reduced toxicity to surrounding healthy tissues [1].

Precision radiotherapy, including image-guided brachytherapy and intensity-modulated radiation therapy (IMRT), is crucial for managing locally advanced ovarian cancer. These techniques allow for higher doses to the tumor while sparing organs at risk, thereby minimizing side effects like gastrointestinal and genitourinary toxicity [2].

Furthermore, adaptive radiotherapy, which allows for daily adjustments to the treatment plan based on changes in tumor size and position, is proving beneficial in ovarian cancer treatment [1].

The integration of radiotherapy with systemic treatments, such as chemotherapy and targeted therapies, is a key area of ongoing research. Studies are investigating optimal sequencing and concurrent delivery to achieve synergistic anti-tumor effects [3].

Radiotherapy techniques are evolving to improve dose escalation in the pelvic and para-aortic regions, which are common sites for recurrence in ovarian cancer. Techniques like volumetric modulated arc therapy (VMAT) offer superior dose conformity compared to traditional IMRT [4].

The role of definitive radiotherapy in specific subsets of ovarian cancer, such as in elderly patients or those with unresectable disease, is also being re-evaluated with these advanced modalities [2].

Quality assurance and adaptive planning are critical for maximizing the benefits of modern radiotherapy in ovarian cancer. This involves meticulous contouring of organs at risk, robust dose calculation algorithms, and regular image verification [6].

Real-time tumor tracking and motion management are also being explored to account for intra-fraction movement during treatment, further enhancing accuracy and efficacy in ovarian cancer radiotherapy [4].

The use of proton therapy in gynecologic malignancies, including ovarian cancer, is being explored. While its widespread adoption is limited by cost and availability, the potential for reduced dose to organs at risk, particularly in the setting of pelvic irradiation, is a key advantage [7].

The identification of biomarkers that predict response to radiotherapy in ovarian cancer is a critical unmet need. Research is focused on genomic, proteomic, and imaging biomarkers that could help stratify patients for radiotherapy and personalize treatment [8].

Conclusion

Radiotherapy for ovarian cancer is advancing with improved imaging techniques like MRI and PET-CT for precise tumor targeting and reduced toxicity. Precision techniques such as IMRT and image-guided brachytherapy allow for higher tumor doses while sparing healthy organs. Adaptive radiotherapy, which adjusts plans daily based on tumor changes, is also showing benefit. Research is exploring the synergistic effects of combining radiation with chemotherapy, targeted therapies, and immunotherapy, aiming to overcome treatment resistance and improve survival. Newer techniques like VMAT and proton therapy are being investigated for better dose delivery and organ sparing. Brachytherapy remains important, particularly for local control. The development of biomarkers to predict radiation response is a key focus for personalized treatment. Stereotactic body radiation therapy (SBRT) is an emerging option for oligometastatic disease.

References

1. Ananya RR, Jason EL, Jiaxu H. (2022) .Seminars in Radiation Oncology 32:180-192.

   , ,

2. Anurag S, D RD, Ashish KG. (2021) .Frontiers in Oncology 11:1-10.

   , ,

3. Kathleen MS, Beth EK, Laura JH. (2023) .Gynecologic Oncology 170:150-158.

   , ,

4. Sushil KJ, Rakesh KG, S ASAK. (2020) .Clinical Oncology 32:e170-e178.

   , ,

5. Hao-Kai W, Jian-Min Z, Yan-Qing L. (2023) .Radiotherapy and Oncology 178:108-119.

   , ,

6. Rui Z, Yilun X, Jun Z. (2020) .Journal of Clinical Oncology 38:2045-2056.

   , ,

7. Jing Z, Yuhui L, Jun S. (2022) .International Journal of Radiation Oncology*Biology*Physics 112:105-115.

   , ,

8. Xiang C, Li W, Bing S. (2021) .Cancers 13:1-15.

   , ,

9. Qing-Yi W, Shuhui L, Weining Z. (2023) .Brachytherapy 22:120-130.

   , ,

10. Charles MR, Charles LS, José B. (2021) .Nature Reviews Clinical Oncology 18:207-223.

    , ,